Indigenous artifacts of Adi tribe in Arunachal Pradesh: Are they waning amidst thewaves of globalization?

The tribals lead the life with natural simplicity relying on primal truths reinforced by eternal values. The strength of the tribes is that they are able to successfully cling to the primal skills and natural simplicity. Their creations speak of evolutions over time, and the arts and crafts created by them have timeless appeal. The primal instinct in all of us is evoked whenever we come across the crudest tribal handicrafts. The present case study was conducted during August and September 2019 and the study included combination of methods such as research viz., household survey of 44 Adi families, followed by a focused group discussion was adopted and also documented the artifacts of Adi tribe in East Siang district of Arunachal Pradesh, India. Further, the study also aimed at unearthing the kinds of possible threats that arise due to globalization which may affect traditional craftsmanship. Multitudinal sets of traditional artifacts created out of indigenous wisdom have beendocumented which affirm that the life of the Adi is intertwined with the forest products especially bamboo, canes and their products. However, the prevailing trend of globalization, with characteristics of immense, unexpected emphasis on capital, labour and information, is having growing influence on material culture and in this scenario, especially new generationprefers more of plastic products in their day to day lifestyle. On the contrary, traditional artifacts of Adi could offer innovative and sustainable solutions which can act as alternatives to plastic products

Biological mechanism and clinical effect of protein-bound polysaccharide K (KRESTIN®): review of development and future perspectives

The mechanism of action of protein-bound polysaccharide K (PSK; KRESTIN®) involves the following actions: (1) recovery from immunosuppression induced by humoral factors such as transforming growth factor (TGF)-β or as a result of surgery and chemotherapy; (2) activation of antitumor immune responses including maturation of dendritic cells, correction of Th1/Th2 imbalance, and promotion of interleukin-15 production by monocytes; and (3) enhancement of the antitumor effect of chemotherapy by induction of apoptosis and inhibition of metastasis through direct actions on tumor cells. The clinical effectiveness of PSK has been demonstrated for various cancers. In patients with gastric or colorectal cancer, combined use of PSK with postoperative adjuvant chemotherapy prolongs survival, and this effect has been confirmed in multiple meta-analyses. For small-cell lung carcinoma, PSK in conjunction with chemotherapy prolongs the remission period. In addition, PSK has been shown to be effective against various other cancers, reduce the adverse effects of chemotherapy, and improve quality of life. Future studies should examine the effects of PSK under different host immune conditions and tumor properties, elucidate the mechanism of action exhibited in each situation, and identify biomarkers

Combination immunotherapy and active-specific tumor cell vaccination augments anti-cancer immunity in a mouse model of gastric cancer

<p>Abstract</p> <p>Background</p> <p>Active-specific immunotherapy used as an adjuvant therapeutic strategy is rather unexplored for cancers with poorly characterized tumor antigens like gastric cancer. The aim of this study was to augment a therapeutic immune response to a low immunogenic tumor cell line derived from a spontaneous gastric tumor of a CEA424-SV40 large T antigen (CEA424-SV40 TAg) transgenic mouse.</p> <p>Methods</p> <p>Mice were treated with a lymphodepleting dose of cyclophosphamide prior to reconstitution with syngeneic spleen cells and vaccination with a whole tumor cell vaccine combined with GM-CSF (a treatment strategy abbreviated as LRAST). Anti-tumor activity to subcutaneous tumor challenge was examined in a prophylactic as well as a therapeutic setting and compared to corresponding controls.</p> <p>Results</p> <p>LRAST enhances tumor-specific T cell responses and efficiently inhibits growth of subsequent transplanted tumor cells. In addition, LRAST tended to slow down growth of established tumors. The improved anti-tumor immune response was accompanied by a transient decrease in the frequency and absolute number of CD4⁺CD25⁺FoxP3⁺T cells (Tregs).</p> <p>Conclusions</p> <p>Our data support the concept that whole tumor cell vaccination in a lymphodepleted and reconstituted host in combination with GM-CSF induces therapeutic tumor-specific T cells. However, the long-term efficacy of the treatment may be dampened by the recurrence of Tregs. Strategies to counteract suppressive immune mechanisms are required to further evaluate this therapeutic vaccination protocol.</p